Nexcelom Bioscience Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nexcelom Bioscience's estimated annual revenue is currently $5.3M per year.(i)
  • Nexcelom Bioscience received $Undisclosed in venture funding in March 2018.
  • Nexcelom Bioscience's estimated revenue per employee is $77,500

Employee Data

  • Nexcelom Bioscience has 68 Employees.(i)
  • Nexcelom Bioscience grew their employee count by -20% last year.

Nexcelom Bioscience's People

NameTitleEmail/Phone
1
Founder & CTO Reveal Email/Phone
2
Head QualityReveal Email/Phone
3
Head SalesReveal Email/Phone
4
VP Strategic Opportunity and CollaborationReveal Email/Phone
5
Head Reagent Development and CommercializationReveal Email/Phone
6
Director Business Development - North America North & EastReveal Email/Phone
7
Product ManagerReveal Email/Phone
8
Project Manager, Training & DevelopmentReveal Email/Phone
9
Field Application ScientistReveal Email/Phone
10
Technical WriterReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Nexcelom Bioscience?

Nexcelom Bioscience is a developer and marketer of image cytometry products for cell analysis in life science and biomedical research. Products range from cell viability counters (Cellometer) to high throughput microwell image cytometry workstations (Celigo), used in thousands of research laboratories in academic institutes, and pharmaceutical and biotech companies. The company contributes to the life science industry through innovation and expertise in the science of cell counting. The product family includes instruments, consumables and reagents. Nexcelom customers engage in a wide variety of research, such as cancer research, immunology, stem cell research, and neuroscience. Nexcelom offers different Cellometer models to count and analyze cell lines and primary cells, through bright field and fluorescence imaging modes. In addition, Celigo is a powerful high image quality, high throughput image cytometry system for adherent and suspension cells in microwell plates. Nexcelom Bioscience is a fast-growing company in a huge market. With its headquarters and manufacturing facilities in the Boston area, the company currently has over 80 global employees, who are fast-paced, customer-centric, helpful to colleagues and customers, and passionate about their impact in life science.

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics

N/A

Total Funding

68

Number of Employees

$5.3M

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nexcelom Bioscience News

2022-04-20 - Image-Based Cytometer Market Prominent Players ...

Image-Based Cytometer Market Prominent Players: ChemoMetec A/S, Nexcelom Bioscience LLC., Vala Sciences Inc., Merck KGaA, GE Healthcare.

2022-04-20 - Global Magnetic Cell Sorter Market 2022 Outlook and COVID ...

Bio-Rad Laboratories; Nexcelom Bioscience; Becton Dickinson; ChemoMetec; RR Mechatronics. The following regions, as well as the...

2022-04-19 - Hemoglobinopathies Market Size, Scope And Outlook | Abbott ...

... Bio-Rad Laboratories Inc., Danaher Corporation, Mindray Medical International Ltd., Nexcelom Bioscience LLC., Nihon Kohden Corporation,...

2018-03-20 - Ampersand Invests in Nexcelom Bioscience

Nexcelom Bioscience, a leading provider of cell counting and analysis products for biomedical research and the biopharma industry, announced today that it has received a strategic investment from Ampersand Capital Partners. The funding will be primarily used to support Nexcelom's worldwide growt ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A6836%N/A
#2
$9.3M69-7%N/A
#3
$16.5M7326%N/A
#4
$7.5M737%N/A
#5
$15M777%N/A

Nexcelom Bioscience Funding

DateAmountRoundLead InvestorsReference
2018-03-21$UndisclosedUndisclosedAmpersand Capital PartnersArticle